Key points are not available for this paper at this time.
The United States Centers for Disease Control and Prevention recently released updated guidance on nonoccupational human immunodeficiency virus postexposure prophylaxis. The guidelines introduce coformulated antiretrovirals as a preferred regimen, which will likely positively impact prescribing practices and adherence. However, other barriers to access and uptake remain a challenge.
Allan‐Blitz et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: